ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
5.24
+0.17 (3.28%)
May 12, 2025, 4:00 PM - Market closed
ImmuCell Employees
As of December 31, 2024, ImmuCell had 75 total employees, including 69 full-time and 6 part-time employees. The number of employees decreased by 4 or -5.06% compared to the previous year.
Employees
75
Change (1Y)
-4
Growth (1Y)
-5.06%
Revenue / Employee
$353,242
Profits / Employee
-$28,755
Market Cap
47.07M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ICCC News
- 11 hours ago - ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025 - GlobeNewsWire
- 4 weeks ago - ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025 - GlobeNewsWire
- 5 weeks ago - ImmuCell Announces Initiation of Investigational Product Use of Re-Tain® - GlobeNewsWire
- 2 months ago - ImmuCell Corporation (ICCC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024 - GlobeNewsWire
- 2 months ago - ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024 - GlobeNewsWire
- 4 months ago - ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses - GlobeNewsWire
- 4 months ago - ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024 - GlobeNewsWire